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ABSTRACT 
 
Variation in platelet response to thrombin may affect the safety and efficacy of PAR antagonism. 
The Thr120 variant of the common single nucleotide polymorphism (SNP) rs773902 in the 
protease-activated receptor (PAR) 4 gene is associated with higher platelet aggregation 
compared to the Ala120 variant. We investigated the relationship between the rs773902 SNP 
with major bleeding and ischemic events, safety, and efficacy of PAR1 inhibition in 6177 NSTE 
ACS patients in the TRACER trial.  There was a lower rate of GUSTO moderate/severe bleeding 
in patients with the Thr120 variant. The difference was driven by a lower rate in the smaller 
homozygous group (recessive model, HR 0.13 [0.02-0.92] p=0.042). No significant differences 
were observed in the ischemic outcomes. The excess in bleeding observed with PAR1 inhibition 
was attenuated in patients with the Thr120 variant, but the interactions were not statistically 
significant. In summary, lower major bleeding rates were observed in the overall TRACER 
cohort with the hyperreactive PAR4 Thr120 variant. The increase in bleeding with vorapaxar 
was attenuated with the Thr120 variant, but we could not demonstrate an interaction with PAR1 
inhibition. These findings warrant further exploration, including those of African ancestry where 
the A allele (Thr120) frequency is ~65%. 
 
Keywords: platelets, PAR1, PAR4, bleeding, pharmacogenetics 
 
Abbreviations: protease activated receptor (PAR), non-ST-segment elevation acute coronary 
syndromes (NSTE ACS), Thrombin Receptor Antagonist for Clinical Event Reduction 
 (TRACER) 
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1. Introduction 
 
 Patients with acute coronary syndromes are at risk of subsequent coronary events due to 
platelet thrombosis on a lipid-rich plaque [1, 2]. Antiplatelet therapies are critical to mitigate the 
risk of atherothrombotic events but at the same time increase the risk of bleeding [2-5]. Bleeding 
complications are associated with increased mortality, and decision of potency and duration of 
antiplatelet medications should be based on the assessment of the risk of thrombotic events vs. 
bleeding complications [6, 7]. There are well-established inter-individual variations in platelet 
reactivity and platelet response to anti-platelet agents, and we have shown there is a substantial 
genetic component to both types of variations [8, 9] that may play a role in determining the risk 
of bleeding and coronary events [10-12]. Many of the challenges with platelet functional assays 
for assessing bleeding and thrombosis risk that can be overcome with nucleic acid-based assays 
[13]. Thus, identifying genetic biomarkers of variation in platelet reactivity may help with risk 
stratification of ischemia and bleeding and improve individual tailoring of antiplatelet 
medications [14-18].  
 Thrombin is the most potent platelet activator, acting through the protease-activated 
receptors (PARs) [19]. The PAR1 receptor has classically been identified as the  primary 
mediator of thrombin effects on human platelets since it is activated at a lower thrombin 
concentration [20]. However, PAR1 signaling is a rapid-on and rapid-off mechanism, whereas 
thrombin-induced PAR4 signaling has slower activation kinetics, but a sustained response. PAR4 
has an overall greater contribution to platelet calcium flux than PAR1 [21, 22]. We have 
previously reported that a single nucleotide dimorphism (G/A), rs773902 of the PAR4 gene 
(F2RL3) determines the Ala120 or Thr120 variants and that the Thr120 variant was associated 
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with higher PAR4 induced platelet aggregation in humans [23]. Notably, the allele frequency of 
rs773902 G or A varies by race, with the G allele more common in whites than blacks (~80% vs. 
37%, respectively) and the A allele less common in whites than blacks (~20% vs. 63%, 
respectively) [24]. Another rare SNP, rs2227346 (only seen on the rs773902 A allele in blacks), 
results in a Phe296Val substitution and the Val 296 variant markedly reduces PAR4 signaling 
[24].  An increased response to thrombin via PAR4 could favor platelet-mediated hemostasis and 
thrombosis events, but it is unknown whether either PAR4 variant modifies the risk of bleeding 
or ischemic events in vivo. In addition, under conditions where PAR1 is nearly fully inhibited, 
such as with the use of the potent PAR1 antagonist vorapaxar, the residual response of platelets 
to thrombin is due to PAR4 activation [25]. Therefore, inter-individual variation in platelet 
PAR4 reactivity could also influence bleeding and thrombotic events in patients treated with 
PAR1 antagonists, and especially bleeding when two different platelet signaling pathways are 
inhibited by aspirin or P2Y12 blockade. 
 Using the platform of the TRACER trial of vorapaxar vs. placebo in patients with non-
ST-segment elevation acute coronary syndromes (NSTE ACS) and the DNA samples collected 
as part of the trial biorepository, we genotyped participants for the rs773902 and rs2227346 
SNPs [26]. The overarching hypothesis of our analysis was that genetically determined 
variability in PAR4 function would influence the risk of bleeding and thrombotic events among 
patients who were treated with vorapaxar. In particular, our goals were to test whether rs773902 
G or A could mitigate the increased risk of major bleeding observed with vorapaxar and to assess 
the effect of PAR4 genetic variability in patients following NSTE ACS. 
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2. Materials and methods 
2.1. The TRACER trial 
The design and results of the TRACER trial have been reported [26]. In brief, the TRACER trial 
included 12,944 patients with NSTE ACS and high-risk features within 24h of hospital 
presentation. Patients were randomized to vorapaxar 40 mg loading dose and 2.5 daily 
maintenance dose or matching placebo. Patients had to be treated for a minimum of one year and 
for the entire duration of the study, which was an event-driven trial. The trial was halted 5 
months prior to its planned conclusion after a Data Safety Monitoring Board review, which 
reported an increased risk of intracranial hemorrhage after the enrollment was completed and the 
minimum number of endpoint events had been reached (median follow up 502 days). In 
TRACER vorapaxar was associated with a non-significant reduction of the primary endpoint, a 
composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia 
with rehospitalization, or urgent coronary revascularization and a nominally significant reduction 
in death from cardiovascular causes, myocardial infarction, stroke. Vorapaxar significantly 
increased GUSTO moderate or severe bleeding and intracranial hemorrhage. 
 A TRACER trial biorepository was created which included blood samples for genetic and 
biomarker analysis. A total of 7,927 consented to the supplemental collection of the genetic 
sample (blood for DNA and RNA analysis). 
 
2.2. Genotyping 
 Blood samples from patients who consented to voluntary participation in the genetic 
substudy were collected in DNA PAXgene tubes (PreAnalytiX, Hombrechtikon, Switzerland) for 
DNA analysis. Because the additional collection of DNA samples was voluntary and subject to 
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individual country regulations, about 60% of the trial cohort had available DNA for genetic 
analysis. Samples were genotyped for rs773902 and rs222736 using TaqMan SNP Genotyping 
Assays (Life Technologies Carlsbad, CA) as previously described [24].  Control DNAs for each 
allele (that had been sequenced) were included on each plate. 
 
2.3. Statistical Analysis 
 Based on the prior platelet function studies, we hypothesized that patients with at least 
one copy of the hyperreactive rs773902 A allele had a decreased rate of major bleeding. We also 
hypothesized that bleeding liability with the PAR1 antagonist vorapaxar would be lower in 
presence of the A allele, as the increased PAR4 function would provide a more effective pathway 
for thrombin-mediated platelet activation through the PAR4. Finally, we hypothesized that 
patients with at least one copy of the rs773902 A allele would have increased risk of ischemic 
events and reduced efficacy from vorapaxar. For this analysis patients were classified in 3 
groups: F2RL3 rs773902 AA homozygous (Thr/Thr120); AG heterozygous (Thr/Ala120), GG 
homozygous (Ala/Ala120) 
 Similarly, we hypothesized that patients with at least one copy of the rs2227346 G allele 
(encodes Val296) are at increased risk of bleeding and relatively higher bleeding risk when 
treated with vorapaxar, compared with placebo.   
 The main bleeding outcomes for the study were non-CABG related GUSTO Moderate 
and Severe and intracranial hemorrhages. The main ischemic outcome was the composite of 
cardiovascular death, myocardial infarction or stroke. The event accrual period for the analysis 
was from hospital discharge to 24 months.   
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 To describe the relationship between the rs773902 and clinical events and their timing, 
Kaplan-Meier (KM) rates stratified by genotype were computed for each endpoint and were 
compared across genotype using the log-rank test. The relationship between the F2RL3 variant 
rs773902 genotype and clinical events was assessed by fitting a Cox proportional hazards model 
for the time-to-first event. The association is characterized by the genotype hazard ratio (HR) 
and the corresponding 95% confidence interval (CI) and p-value. TRACER used self-identified 
race and ethnicity (called “race”). To minimize population confounders, self-identified non-white 
patients were excluded in the primary analysis.  This analysis was repeated modeling the 
rs773902 genotype under an additive, dominant, and recessive model. 
 To describe the relationship between rs773902 and rs227346 variants, vorapaxar and 
clinical event Kaplan-Meier rates were calculated by genotype overall and by treatment arm for 
each endpoint of interest. Event counts were compared across genotype using the log-rank test. 
To determine if the relationship between vorapaxar and clinical events differ by rs773902 
genotype, an interaction term between genotype and treatment arm was included in the model 
and tested. The relationship between treatment and outcome was characterized by the vorapaxar 
vs. placebo HR and the corresponding 95% CI within each genotype and by the interaction p-
value. 
 
3. Results 
 
3.1. TRACER PAR4 Genetic Substudy participants 
 Of the 12944 patients included in the TRACER trial 7927 individual agreed to participate 
in the Genetic Substudy (Figure 1). Among these, sufficient material for DNA analysis was 
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collected in 6890 subjects. 632 non-white patients were not included. For 81 patients it was not 
possible to match the sample ID to the main trial database (i.e., genetic data are de-identified and 
not kept into the main trial database). The final sample size for this PAR4 Genetic Study analysis 
included 6177 patients, and the baseline characteristics are shown in Table 1.  The PAR4 Genetic 
Study is representative of the entire TRACER study except for the limitation to white subjects in 
the PAR4 Genetic Study; the demographic variables are similar across all genotypes. 
 
3.2. F2RL3 Genotypes 
 The rs773902 SNP was successfully genotyped in 99.5% of samples; 31 could not be 
definitively assigned a genotype.  The rs773902 genotypes for the entire cohort showed that 
3884 (63.2%) patients were G/G genotype, 1995 (32.4%) were A/G and 267 (4.3%) were A/A 
genotype.  The rare rs2227346 G allele was present in 15 patients (0.2%), all of whom were 
heterozygous G/T; no homozygous G/G subjects were present in our cohort. Given the small 
number of patients with the rare rs2227346 G allele, we did not test for associations of this allele 
with further event rates or interaction with vorapaxar. 
 
3.3. F2RL3 Genotypes and Bleeding Outcomes 
 In the PAR4 Genetic Study, there was a lower rate of GUSTO moderate or severe 
bleeding with the presence of the A allele (p=0.053) (Table 2). As shown in Table 3, the 
association between bleeding and genotype was not statistically significant using the additive 
genetic model (HR 0.84, 95% CI 0.64 - 1.11) or dominant genetic model (HR 0.93, 95%CI 0.68-
1.28). The recessive genetic model showed a significant reduction in the risk of bleeding 
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associated with the allele A (HR 0.13, 95%CI 0.02-0.92), suggesting a bleeding risk reduction 
with the presence of 2 copies of the hyperactive A allele.   
 In our analysis cohort, only 22 intracranial hemorrhages were observed by 24 months 
post-discharge. None of the ICH as observed in the homozygous AA group, while the rate of 
ICH was 0.4% in the AG and 0.8% in the GG group.  
 
3.4. F2RL3 Genotypes and Ischemic Outcomes 
 There were no significant differences in the occurrence of cardiovascular death, 
myocardial infarction or stroke according to the F2RL3 genotypes (Table 2). Numerical 
imbalances observed were contrary to the study hypothesis, with lower rates in the AA group. 
The additive, dominant and recessive models were all non-significant (Table 3).  
 
3.5. Vorapaxar Effect on Bleeding by F2RL3 Genotypes  
 We next estimated the treatment difference among genotypes. The relative increase in 
GUSTO moderate or severe bleeding observed with vorapaxar was higher in the GG group, 
known to have lower platelet PAR4 reactivity (Table 4).  Because the number of bleeding events 
was too small to perform a recessive model analysis, we considered patients with at least one 
copy of the A allele (i.e., a dominant model).  As shown in Table 5, the Hazard Ratio of bleeding 
with vorapaxar in this group was 1.06 (95% CI 0.64 - 1.78), while in the GG group the HR was 
1.45 (95% CI 0.99 – 2.13). The interaction term was not statistically significant.  
 The number of intracranial hemorrhages was overall low. There were no intracranial 
hemorrhages in patients with AA genotypes. In patients with AG genotypes, there was a doubled 
rate of intracranial hemorrhage with vorapaxar v. placebo (0.3% vs. 0.6%). In patients in the GG 
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group there we observed a 7-fold increase in the occurrence of intracranial hemorrhage with 
vorapaxar compared to placebo (1.4% vs. 0.2%). In the dominant model, among patients with at 
least one copy of the A allele, the Hazard Ration of intracranial hemorrhage with vorapaxar was 
1.50 (95% CI 0.25 – 8.98), while in the GG group the HR was 2.69 (95% CI  0.71- 10.13). 
 
3.6. Vorapaxar Effect on Ischemic Outcomes by F2RL3 Genotypes  
 A reduction in cardiovascular death, myocardial infarction or stroke with vorapaxar was 
observed in all groups (Table 2), but there was no significant interaction between genotypes and 
treatment using the additive, dominant or recessive models. 
 
 
4. Discussion 
 
 Inhibition of the PAR1 thrombin receptor provides benefit in the secondary prevention of 
ACSs in some settings, but its use has been limited due to concerns of major bleeding.  The 
rationale for the current study was to identify a genetic predictor that could identify patients with 
a lower bleeding risk in the setting of anti-platelet therapies. To our knowledge this is the first 
study testing for associations between a common thrombin receptor polymorphism and clinical 
outcomes in a large, randomized clinic trial of patients with NSTE ACS [26]. Although thrombin 
receptors have a broad tissue distribution, our hypotheses were based on abundant in vitro data 
using human blood that demonstrated enhanced platelet activation and aggregation from healthy 
individuals expressing the rs773902 A allele encoding Thr in the PAR4 thrombin receptor [23, 
24, 27]. The most important finding from our work was that the rs773902 AA genotype 
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conferred a significant reduction in GUSTO moderate or severe bleeding.  Our findings may 
have implications for the future development of PAR inhibitors generally, and for PAR4 
inhibitors specifically [28, 29]. 
 The major physiologic role for platelets is to maintain hemostasis, and thrombocytopenia 
and platelet dysfunction are well-established risks for bleeding. Anti-platelet therapy with aspirin 
and P2Y12 inhibition block secondary feedback pathways of platelet activation and have become 
standards of care for secondary prevention of ACSs. The development of effective anti-platelet 
agents that inhibit a third, though primary, activation pathway has the difficult challenge of 
demonstrating clinical benefit in the face of likely enhanced bleeding with triple anti-platelet 
therapy. Indeed, this challenge has appeared to be the case with vorapaxar, which inhibits the 
PAR1 thrombin receptor. Our analyses showed that patients homozygous for the rs773902 A 
allele had less GUSTO severe/moderate bleeding, which is consistent with a mechanism 
whereby the hyperactive Thr120 PAR4 isoform promotes normal hemostasis. Smaller numbers 
of patients met the criteria for TIMI major or minor bleeding, but trends in the same direction 
were observed (not shown).  While we could not demonstrate an interaction between vorapaxar 
use and rs773902, a significant increase in bleeding was observed in the GG group only.  And 
since most patients in TRACER were using both aspirin and a P2Y12 inhibitor, the enhanced 
hemostasis with the A allele is also consistent with in vitro studies showing platelets from donors 
expressing the rs773902 A allele are less sensitive to the inhibitory effects of both aspirin and 
P2Y12 inhibition [27]. Notably, our modeling of the effect of the A alleles showed a significant 
reduction in bleeding in the whole population only with the recessive model, suggesting that two 
copies of the A allele may be required to significantly modify the bleeding tendency in 
TRACER. The additive and dominant model showed a directionally consistent result but were 
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not statistically significant. The Thr for Ala substitution at residue 120 in the 2nd transmembrane 
domain of PAR4 changes a nonpolar residue to a polar residue, which could favor PAR4 
homodimerization [30] and enhanced signaling in the homozygous state.  
 We did not observe an association between rs773902 A and ischemic events. This 
observation was not entirely unexpected since, unlike hemostasis where platelets play a central 
and critical role, atherothrombosis is a complex and multifactorial disease, involving other 
pathophysiologic mechanisms such as elevated blood pressure, altered glucose or lipid 
metabolism, endothelial dysfunction, etc. Our hypotheses were based on in vitro platelet studies, 
but PARs have other platelet-independent functions, and are involved in response to injury and 
inflammation and their proteases may signal differently in other cells. There are no data on the 
functional effect of the PAR4 variant in non-platelet tissues [31, 32], and perhaps the lack of an 
association of rs773902 with ischemic outcomes in TRACER is related to unknown effects of the 
PAR4 variants to the vasculature [33, 34]. Moreover, atherothrombosis is a complex and 
multifactorial disease and not determined by single gene, therefore a single genetic variant may 
have a relatively minor effect on the onset and progression of the disease.  
 This study had several limitations. First, this was a selected cohort of patients randomized 
in a clinical trial after suffering an NSTE ACS. Because patients during the acute period were 
treated with multiple antithrombotic therapies and had undergone invasive procedures, we 
decided to start the accrual period for the analyses at the time of discharge from the index 
hospitalization. While this selection was arbitrary, it is a standard time point for post-ACS 
studies, and we believe that this selection allowed an adequate assessment of the effect of the 
genotypes in our cohort. Finally, the prevalence of homozygous AA in our cohort was small, 
accounting for slightly over 4% of the populations. This low prevalence means that, if in fact, a 
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significant effect on bleeding requires homozygous status, our study may have been 
underpowered.  At the same time, although biologically plausible and in line with the study 
hypothesis, a chance finding is also possible given the small group size.  
 The findings of this analysis are limited to an NSTE ACS cohort of patients who were 
discharged from an acute event.  Despite these limitations, our analysis is the first assessment in 
a large cohort of the association between PAR4 genotypes and bleeding and the potential impact 
of PAR4 genotypes on safety and efficacy of concomitant PAR1 inhibition. 
 We conclude that the SNP rs7773902 of PAR4 gene may influence the bleeding risk and 
bleeding liability with vorapaxar after an NSTE ACS, especially in allele A homozygotes. 
Further studies are needed to confirm this finding. Our findings may be of particular relevance 
for patients of African descent ~40% of whom are homozygous AA for rs7773902, while the 
TRACER population only included 2.5% of African American [24]. In data not shown, when 
blacks were included in our analyses, none of the results materially changed, with only a 
minimal change in the rate of GUSTO moderate or severe bleeding with the presence of the A 
allele (p=0.035).  Our study should serve as basis for future studies that include sufficient 
numbers of African Americans or patients with other cardiovascular conditions, such as those 
with chronic stable disease. It will also be important to consider PAR4 functional variants in 
those on-going trials of PAR4 antagonists in platelet-mediated cardiovascular diseases [28, 29] 
or other conditions where PAR4 or race may play a pathophysiologic role. 
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Figure 1. Consort Diagram 
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Table 1. Baseline characteristics 
 
Table 1. Baseline characteristics by study cohort and by genotype of the F2RL3 variant rs773902 
   By Genotype of the F2RL3 Variant rs773902 
 
TRACER  
Trial Cohort 
Analysis  
Cohort  
A/A A/G G/G 
Cohort Size 12944 6117 267 1995 3884 
Age 64.0 (58.0 - 72.0) 64.0 (58.0 - 72.0) 64.0 (58.0 - 72.0) 64.0 (58.0 - 72.0) 64.0 (58.0 - 72.0) 
Male 9312 (71.9%) 4414 (71.5%) 190 (71.2%) 1431 (71.7%) 2772 (71.4%) 
Race      
White 11039 (85.3%) 6177 (100.0%) 267 (100.0%) 1995 (100.0%) 3884 (100.0%) 
Asian 1056 (8.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Other 814 (6.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Weight (kg) 80.0 (70.0 - 92.4) 83.0 (73.0 - 95.0) 83.9 (74.4 - 95.0) 82.5 (72.0 - 95.0) 83.0 (73.0 - 95.0) 
Hypertension 9128 (70.5%) 4349 (70.4%) 180 (67.4%) 1427 (71.5%) 2721 (70.1%) 
Hyperlipidemia 8062 (62.3%) 3901 (63.2%) 162 (60.7%) 1239 (62.1%) 2476 (63.7%) 
Diabetes 4070 (31.5%) 1813 (29.4%) 92 (34.5%) 589 (29.5%) 1119 (28.8%) 
Current Tobacco Use 3536 (27.3%) 1666 (27.0%) 74 (27.7%) 562 (28.2%) 1026 (26.4%) 
History of MI 3791 (29.3%) 1814 (29.4%) 80 (30.0%) 576 (28.9%) 1152 (29.7%) 
History of PCI 3090 (23.9%) 1461 (23.7%) 55 (20.6%) 450 (22.6%) 948 (24.4%) 
History of CABG 1543 (11.9%) 758 (12.3%) 41 (15.4%) 245 (12.3%) 468 (12.0%) 
History of Stroke 553 (4.3%) 236 (3.8%) 12 (4.5%) 79 (4.0%) 142 (3.7%) 
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Table 1. Baseline characteristics by study cohort and by genotype of the F2RL3 variant rs773902 
   By Genotype of the F2RL3 Variant rs773902 
 
TRACER  
Trial Cohort 
Analysis  
Cohort  
A/A A/G G/G 
Region      
Asia/Pacific 1366 (10.6%) 258 (4.2%) 12 (4.5%) 81 (4.1%) 164 (4.2%) 
Eastern EU 1487 (11.5%) 1081 (17.5%) 42 (15.7%) 349 (17.5%) 688 (17.7%) 
North America 3404 (26.3%) 1837 (29.7%) 76 (28.5%) 589 (29.5%) 1153 (29.7%) 
South America 848 (6.6%) 119 (1.9%) 4 (1.5%) 45 (2.3%) 70 (1.8%) 
Western EU 5839 (45.1%) 2882 (46.7%) 133 (49.8%) 931 (46.7%) 1809 (46.6%) 
Clopidogrel at 
Randomization 
11608 (89.7%) 5562 (90.0%) 238 (89.1%) 1784 (89.4%) 3510 (90.4%) 
MI at enrollment 12050 (93.7%) 5778 (94.2%) 252 (95.5%) 1859 (93.8%) 3637 (94.3%) 
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Table 2 – Event rates by rs773902 genotypes, overall and by treatment arm 
 Overall  Vorapaxar Arm Placebo Arm  
Genotype  A/A A/G G/G P A/A A/G G/G P A/A A/G G/G P 
Cohort Size 267 1995 3884 --- 138 1002 1941 --- 129 993 1943 --- 
Bleeding             
Gusto 
Severe/Moderate 
1 (0.4%) 57 (3.8%) 108 (3.8%) 0.053 0 (0.0%) 30 (3.8%) 64 (4.6%) 0.092 1 (0.9%) 27 (3.7%) 44 (2.9%) 0.357 
Intracranial 
Hemorrhage  
0 (0.0%) 6 (0.4%) 16 (0.8%) 0.483 0 (0.0%) 4 (0.6%) 13 (1.4%) 0.440 0 (0.0%) 2 (0.3%) 3 (0.2%) 0.856 
             
Ischemic 
Outcomes 
            
CV 
Death/MI/Stroke 
14 (6.1%) 179 (11.5%) 328 (10.9%) 0.102 5 (3.7%) 76 (9.5%) 153 (10.1%) 0.190 9 (8.6%) 103 (13.4%) 175 (11.8%) 0.303 
CV Death 4 (1.5%) 47 (3.2%) 77 (2.6%) 0.475 2 (1.5%) 22 (3.0%) 37 (2.5%) 0.743 2 (1.6%) 25 (3.3%) 40 (2.7%) 0.639 
MI 11 (4.7%) 130 (8.1%) 245 (8.2%) 0.280 4 (3.0%) 54 (6.7%) 109 (7.1%) 0.391 7 (6.6%) 76 (9.5%) 136 (9.3%) 0.575 
Stroke 1 (0.7%) 27 (2.3%) 38 (1.4%) 0.201 0 (0.0%) 9 (1.2%) 20 (1.5%) 0.476 1 (1.4%) 18 (3.3%) 18 (1.3%) 0.103 
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Table 3 – Models of effect of rs773902 genotypes on bleeding and ischemic outcomes in the analysis cohort 
 Additive Genetic Model Dominant Genetic Model Recessive Genetic Model  
Endpoint HR
 (95% CI)  P-Value HR (95% CI)  P-Value HR (95% CI)  P-Value 
Bleeding       
Gusto Severe/Moderate  0.84 (0.64 - 1.11) 0.221 0.93 (0.68 - 1.28) 0.666 0.13 (0.02 - 0.92) 0.042 
Intracranial Hemorrhage* 0.61 (0.26 - 1.45) 0.265 0.65 (0.25 - 1.66) 0.367 --- --- 
Efficacy       
CV Death/MI/Stroke 0.96 (0.82 - 1.11) 0.565 1.02 (0.85 - 1.21) 0.867 0.59 (0.34 - 1.00) 0.049 
CV Death 1.06 (0.79 - 1.42) 0.717 1.14 (0.80 - 1.63) 0.459 0.70 (0.26 - 1.88) 0.475 
MI 0.95 (0.79 - 1.13) 0.548 0.99 (0.81 - 1.22) 0.956 0.63 (0.34 - 1.14) 0.126 
Stroke 1.09 (0.72 - 1.64) 0.689 1.27 (0.78 - 2.08) 0.330 0.33 (0.05 - 2.37) 0.269 
Hazard Ratios show risk associated with allele A 
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Table 4 – Safety and Efficacy of Vorapaxar by rs773902  
Genotype  A/A  A/G  G/G   
 Vorapaxar Placebo 
HR (95% 
CI) 
Vorapaxar Placebo 
HR (95% CI) 
Vorapaxar Placebo 
HR (95% CI) P-Int  
Cohort Size 138 129  1002 993  1941 1943   
Bleeding           
Gusto 
Severe/Moderate 
0 (0.0%) 1 (0.9%) 
NA 
30 (3.8%) 27 (3.7%) 
NA 
64 (4.6%) 44 (2.9%) 
NA 0.678 
Intracranial 
Hemorrhage  
0 (0.0%) 0 (0.0%) 
NA 
4 (0.6%) 2 (0.3%) 
NA 
13 (1.4%) 3 (0.2%) 
NA NA 
           
Ischemic 
Outcomes 
  
 
  
 
  
  
CV 
Death/MI/Stroke 
5 (3.7%) 7 (5.7%) 
0.60 (0.36 - 
1.01) 
76 (9.5%) 9 (8.6%) 
0.72 (0.55 - 
0.92) 
153 
(10.1%) 
103 
(13.4%) 
0.85 (0.69 - 
1.05) 
0.225 
CV Death 2 (1.5%) 2 (1.6%) 
0.87 (0.32 - 
2.34) 
22 (3.0%) 2 (1.6%) 
0.89 (0.55 - 
1.44) 
37 (2.5%) 25 (3.3%) 
0.91 (0.59 - 
1.40) 
0.932 
MI 4 (3.0%) 6 (5.0%) 
0.60 (0.33 - 
1.11) 
54 (6.7%) 7 (6.6%) 
0.69 (0.51 - 
0.93) 
109 (7.1%) 76 (9.5%) 
0.78 (0.61 - 
1.00) 
0.469 
Stroke 0 (0.0%) 0 (0.0%) NA 9 (1.2%) 1 (1.4%) NA 20 (1.5%) 18 (3.3%) NA NA 
HR comparing vorapaxar vs. placebo in each of genotypes. HR and P-value not calculated when one of the group had 0 events. P-int: 
P-value for interaction. 
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Table 5 – Hazard of bleeding and ischemic event with vorapaxar by dominant genotype 
 
HR (95% CI) Vorapaxar vs. 
Placebo 
 
Genotype  A/A and A/G G/G P-Int 
Bleeding    
Gusto Severe/Moderate 1.06 (0.64 - 1.78)) 
1.45 (0.99 - 
2.13) 
0.342 
Intracranial 
Hemorrhage  
2.02 (0.37 - 11.04) 
4.39 (1.25 - 
15.40) 
0.472 
    
Ischemic Outcomes    
CV Death/MI/Stroke 0.70 (0.53 - 0.94) 
0.85 (0.69 - 
1.06) 
0.292 
CV Death 0.88 (0.51 - 1.53) 
0.92 (0.59 - 
1.43) 
0.917 
MI 0.68 (0.49 - 0.95) 
0.78 (0.61 - 
1.01) 
0.342 
Stroke 0.47 (0.21 - 1.03) 
1.10 (0.58 - 
2.08) 
0.100 
P-int: P-value for interaction. 
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